Ferring Announces U.S. FDA Advisory Committee Meeting for SI-6603 (condoliase), An Investigational Treatment in Lumbar Disc Herniation

Autor:	Ferring Pharmaceuticals
Zdroj:	Business Wire (English). 12/02/2024.
Abstrakt:	Ferring Pharmaceuticals and its clinical development partner, Seikagaku Corporation (Seikagaku), today announced that the Anesthetic and Analgesic Drug Products Advisory Committee of the U.S. Food and Drug Administration (FDA) will hold a meeting on January 10, 2025, to review data supporting the biologics license application (BLA) for SI-6603 (generic name: condoliase), an investigational product being studied for the treatment of radicular leg pain associated with lumbar disc herniation (LDH) in adults. [ABSTRACT FROM PUBLISHER]
Databáze:	Regional Business News
Externí odkaz:	Zobrazit plný text záznamu Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.